Home
Team
Russell Hirsch
David Schnell
Lisa Potocsnak
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News

Prospect Venture Partners

Home
Team
Russell Hirsch
David Schnell
Lisa Potocsnak
Alex Barkas, In Memoriam
About
What We Do
What We've Achieved
Contact
Portfolio
News
David Schnell
September 5, 2017

Sep 5, 2017 - Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory (NTM) Lung Disease

David Schnell
September 5, 2017

Source: http://investor.insmed.com/releasedetail.cfm?releaseid=1039069

Newer PostSept 11, 2017 - Insmed Announces Closing of Public Offering
Older PostJune 7, 2017 - SentreHEART aMAZE Trial Receives FDA Approval for Stage II

Contact Prospect
Venture Partners:

Address:
525 University Ave., Suite 1350
Palo Alto, CA 94301

Phone:
(650) 327-8800

Prospect Ventures Funds:
Prospect Venture Partners I
Prospect Venture Partners II
Prospect Venture Partners III

 Connect with Prospect Ventures:
 Prospect Ventures on LinkedIn
 Prospect Ventures on Crunchbase
 Prospect Ventures on Bloomberg
 Prospect Ventures on CB Insights
 Prospect Ventures on Palico
 Prospect Ventures on Index.co
 Prospect Bio Ventures

Back to Top

© 2018 - Prospect Venture Partners.. All Rights Reserved
No content on this site may be republished or reprinted without written permission from Prospect Venture Partners